The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.
The two partners have presented updated results from the phase 2b KEYNOTE-942 trial of the mRNA-4157 vaccine, given in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...